Trial Outcomes & Findings for Low-Cost Platelet-Rich Plasma for Hemarthropathy (NCT NCT06543368)

NCT ID: NCT06543368

Last Updated: 2026-02-27

Results Overview

Global patient satisfaction was assessed prospectively at 6 months following the intervention using a numeric rating scale ranging from 0 to 100. Participants were asked to rate their overall satisfaction with the treatment outcome, where 0 represented "not satisfied" and 100 represented "completely satisfied." The score reflects the participant's overall perception of their injection, including symptom improvement and overall experience.

Recruitment status

COMPLETED

Study phase

NA

Target enrollment

14 participants

Primary outcome timeframe

6-months

Results posted on

2026-02-27

Participant Flow

Patients who are eligible for a standard-of-care injection were enrolled from the Utah Center for Bleeding and Clotting Disorders. If the participant appeared to be a candidate, he or she was invited to participate.

This was an open-label study; therefore, no randomization was performed. The joint enrolled was selected collaboratively by the principal investigator and the patient, based on which joint was causing the greatest symptoms. In some cases, participants had more than one joint enrolled (e.g., one knee and one ankle), accounting for the difference between the number of participants (n=14) and the number of units/joints enrolled (n=20).

Unit of analysis: Joints

Participant milestones

Participant milestones
Measure
PRP Injection
A total of 20 joints (14 patients) received PRP injections, performed at day 0 and 3 weeks, for a total of two injections. All subjects received ultrasound-guided intra-articular joint injections by an experienced sports medicine provider after local anesthesia with 1% lidocaine to the extra-articular structures, namely the skin and joint capsule, to increase comfort. These will be performed after the patient's typical factor infusions.
Overall Study
STARTED
14 20
Overall Study
Knees Assessed
5 7
Overall Study
Ankles assessed
9 10
Overall Study
Elbows assessed
3 3
Overall Study
COMPLETED
14 20
Overall Study
NOT COMPLETED
0 0

Reasons for withdrawal

Withdrawal data not reported

Baseline Characteristics

14 participants were enrolled, however some participants had multiple joints injected.

Baseline characteristics by cohort

Baseline characteristics by cohort
Measure
PRP Injection
n=20 Joints
45mL of blood is drawn from the subject in a standard-of-care manner into 3 x 20mL syringes, each containing 2mL of sodium citrate (anticoagulant). Each syringe is prepared and capped, then placed into a centrifuge. The resulting separated blood is then drawn off into a single new sterile syringe, which can be used for the injection. Blood and PRP analysis: We will perform a full analysis (a complete blood count \[CBC\] with differential) on subjects' whole blood and their prepared LC-PRP. Importantly, we will include all data required in the PRP minimum reporting standards, including "platelet, differential leukocyte, and red cell analysis of all samples."
Age, Categorical
<=18 years
0 Participants
n=14 Participants
Age, Categorical
Between 18 and 65 years
14 Participants
n=14 Participants
Age, Categorical
>=65 years
0 Participants
n=14 Participants
Sex: Female, Male
Female
0 Participants
n=14 Participants
Sex: Female, Male
Male
14 Participants
n=14 Participants
Hemophilia Type
Hemophilia type A
12 Participants
n=14 Participants
Hemophilia Type
Hemophilia type B
2 Participants
n=14 Participants
Hemophilia Severity
Mild
2 Participants
n=14 Participants
Hemophilia Severity
Moderate
1 Participants
n=14 Participants
Hemophilia Severity
Severe
11 Participants
n=14 Participants
Baseline Satisfaction with Joint
Very unsatisfied
3 Joints
n=20 Joints • 14 participants were enrolled, however some participants had multiple joints injected.
Baseline Satisfaction with Joint
Unsatisfied
14 Joints
n=20 Joints • 14 participants were enrolled, however some participants had multiple joints injected.
Baseline Satisfaction with Joint
Neither satisfied nor unsatisfied
1 Joints
n=20 Joints • 14 participants were enrolled, however some participants had multiple joints injected.
Baseline Satisfaction with Joint
Satisfied
2 Joints
n=20 Joints • 14 participants were enrolled, however some participants had multiple joints injected.
Baseline Satisfaction with Joint
Very Satisfied
0 Joints
n=20 Joints • 14 participants were enrolled, however some participants had multiple joints injected.

PRIMARY outcome

Timeframe: 6-months

Global patient satisfaction was assessed prospectively at 6 months following the intervention using a numeric rating scale ranging from 0 to 100. Participants were asked to rate their overall satisfaction with the treatment outcome, where 0 represented "not satisfied" and 100 represented "completely satisfied." The score reflects the participant's overall perception of their injection, including symptom improvement and overall experience.

Outcome measures

Outcome measures
Measure
PRP Injection
n=20 Joints
45mL of blood is drawn from the subject in a standard-of-care manner into 3 x 20mL syringes, each containing 2mL of sodium citrate (anticoagulant). Each syringe is prepared and capped, then placed into a centrifuge. The resulting separated blood is then drawn off into a single new sterile syringe, which can be used for the injection. Blood and PRP analysis: We will perform a full analysis (a complete blood count \[CBC\] with differential) on subjects' whole blood and their prepared LC-PRP. Importantly, we will include all data required in the PRP minimum reporting standards, including "platelet, differential leukocyte, and red cell analysis of all samples."
Global Satisfaction (Numeric Rating System)
70 Scores on a scale
Interval 35.0 to 100.0

SECONDARY outcome

Timeframe: 6-months

Description: The Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) is a validated measure designed to assess pain, stiffness, and physical function in individuals with hip or knee osteoarthritis. Structure: The WOMAC consists of 24 items divided into three subscales: Pain (5 items): pain during walking, using stairs, lying/sitting, standing, and at night. Stiffness (2 items): stiffness after first waking and later in the day. Physical Function (17 items): difficulty with daily activities such as rising from sitting, bending, walking, getting in/out of a car, shopping, and stair use. Each item is rated using a 5-point Likert scale: 0 (none) - 4 (extreme) Scoring: Subscale scores are summed - Pain: 0-20 Stiffness: 0-8 Physical Function: 0-68 The total score is the sum of all items (range 0-96), with higher scores indicating worse symptoms.

Outcome measures

Outcome measures
Measure
PRP Injection
n=7 Knees
45mL of blood is drawn from the subject in a standard-of-care manner into 3 x 20mL syringes, each containing 2mL of sodium citrate (anticoagulant). Each syringe is prepared and capped, then placed into a centrifuge. The resulting separated blood is then drawn off into a single new sterile syringe, which can be used for the injection. Blood and PRP analysis: We will perform a full analysis (a complete blood count \[CBC\] with differential) on subjects' whole blood and their prepared LC-PRP. Importantly, we will include all data required in the PRP minimum reporting standards, including "platelet, differential leukocyte, and red cell analysis of all samples."
Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC)
Pain Subscore
7 Scores on a scale
Interval 0.0 to 18.0
Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC)
Total Score
31 Scores on a scale
Interval 0.0 to 73.0
Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC)
Stiffness Subscore
4 Scores on a scale
Interval 0.0 to 9.0
Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC)
Functionality Subscore
21 Scores on a scale
Interval 0.0 to 46.0

SECONDARY outcome

Timeframe: 6-months

The Quick Disabilities of the Arm, Shoulder, and Hand (QuickDASH) is a validated outcome measure designed to assess physical function and symptoms in individuals with upper-extremity musculoskeletal conditions. Structure: The QuickDASH consists of 11 items derived from the original 30-item DASH questionnaire. Items assess: Difficulty performing common physical tasks. Severity of upper-extremity symptoms. Impact on sleep, work, and social activities Optional modules (Work and Sports/Performing Arts) may each be added as separate 4-item scales if relevant. Response Scale: Likert scale ranging from 1 (No difficulty / No symptom) to 5 (Unable to do / Extreme symptom) Scoring: Items are averaged, converted to a 0-100 scale using the formula: ((mean score - 1) × 25) Total score range: 0-100, where higher scores indicate greater disability and worse upper-extremity function.

Outcome measures

Outcome measures
Measure
PRP Injection
n=3 Elbows
45mL of blood is drawn from the subject in a standard-of-care manner into 3 x 20mL syringes, each containing 2mL of sodium citrate (anticoagulant). Each syringe is prepared and capped, then placed into a centrifuge. The resulting separated blood is then drawn off into a single new sterile syringe, which can be used for the injection. Blood and PRP analysis: We will perform a full analysis (a complete blood count \[CBC\] with differential) on subjects' whole blood and their prepared LC-PRP. Importantly, we will include all data required in the PRP minimum reporting standards, including "platelet, differential leukocyte, and red cell analysis of all samples."
Quick Disabilities of Arm Shoulder and Hand (QuickDASH)
22.73 Scores on a scale
Interval 0.0 to 56.82

SECONDARY outcome

Timeframe: 6-months

The Foot and Ankle Outcome Score (FAOS) functional score is a validated measure designed to assess the functional limitations of the foot and ankle Structure: The functional portion of the FAOS consists of 17 items related to activities of Daily Living Response Scale: Each item is scored using a 5-point Likert scale ranging from: 0 (No problems) - 4 (Extreme problems) Scoring: Each subscale scores are transformed to a 0-100 scale using: Individual scores are totaled 100 - (((functional score total) × 100) /68) Score range per subscale: 0-100, where 100 represents no symptoms and full function, and 0 represents extreme symptoms and maximal functional limitations

Outcome measures

Outcome measures
Measure
PRP Injection
n=10 Ankles
45mL of blood is drawn from the subject in a standard-of-care manner into 3 x 20mL syringes, each containing 2mL of sodium citrate (anticoagulant). Each syringe is prepared and capped, then placed into a centrifuge. The resulting separated blood is then drawn off into a single new sterile syringe, which can be used for the injection. Blood and PRP analysis: We will perform a full analysis (a complete blood count \[CBC\] with differential) on subjects' whole blood and their prepared LC-PRP. Importantly, we will include all data required in the PRP minimum reporting standards, including "platelet, differential leukocyte, and red cell analysis of all samples."
Foot and Ankle Outcome Score (FAOS): Function
94.12 Scores on a scale
Interval 84.12 to 100.0

Adverse Events

PRP Injection

Serious events: 0 serious events
Other events: 9 other events
Deaths: 0 deaths

Serious adverse events

Adverse event data not reported

Other adverse events

Other adverse events
Measure
PRP Injection
n=20 participants at risk
45mL of blood is drawn from the subject in a standard-of-care manner into 3 x 20mL syringes, each containing 2mL of sodium citrate (anticoagulant). Each syringe is prepared and capped, then placed into a centrifuge. The resulting separated blood is then drawn off into a single new sterile syringe, which can be used for the injection. Blood and PRP analysis: We will perform a full analysis (a complete blood count \[CBC\] with differential) on subjects' whole blood and their prepared LC-PRP. Importantly, we will include all data required in the PRP minimum reporting standards, including "platelet, differential leukocyte, and red cell analysis of all samples."
Musculoskeletal and connective tissue disorders
Increased pain in the joint
25.0%
5/20 • From enrollment, to 6 months
Musculoskeletal and connective tissue disorders
Reduced joint range of motion
5.0%
1/20 • From enrollment, to 6 months
Musculoskeletal and connective tissue disorders
New swelling of the joint (not due to joint bleed)
5.0%
1/20 • From enrollment, to 6 months
Musculoskeletal and connective tissue disorders
Other
10.0%
2/20 • From enrollment, to 6 months

Additional Information

Jamie Egbert

University of Utah

Phone: 8015871532

Results disclosure agreements

  • Principal investigator is a sponsor employee
  • Publication restrictions are in place